Seeking Alpha

Kadcyla wins EU marketing approval triggering milestone payment for ImmunoGen

  • Roche (RHHBY -0.4%) and ImmunoGen's (IMGN +1.8%) Kadcyla gets European marketing approval, triggering a $5M milestone payment to IMGN.
  • The drug is approved for adults with "HER2-positive, unresectable locally advanced or metastatic breast cancer who previously received Herceptin and a taxane, separately or in combination." (PR)
  • The news was expected after the CHMP gave the drug a positive opinion back in September.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: